The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program
Open accessAbstract
BACKGROUND: Australia's National Cervical Screening Program currently recommends cytological screening every 2 years for women aged 18-69 years. Human papillomavirus (HPV) vaccination was implemented in 2007 with high population coverage, and falls in high-grade lesions in young women have been reported extensively. This decline prompted a major review of the National Cervical Screening Program and new clinical management guidelines, for which we undertook this analysis. METHODS: We did effectiveness modelling and an economic assessment of potential new screening strategies, using a model of HPV transmission, vaccination, natural history, and cervical screening. First, we evaluated 132 screening strategies, including those based on cytology and primary HPV testing. Second, after a recommendation was made to adopt primary HPV screening with partial genotyping and direct referral to colposcopy of women positive for HPV16/18, we evaluated the final effect of HPV screening after incorporating new clinical guidelines for women positive for HPV. Both evaluations considered both unvaccinated and vaccinated cohorts. FINDINGS: Strategies entailing HPV testing every 5 years and either partial genotyping for HPV16/18 or cytological co-testing were the most effective. One of the most effective and cost-effective strategies comprised primary HPV screening with referral of women positive for oncogenic HPV16/18 direct to colposcopy, with reflex cytological triage for women with other oncogenic types and direct referral for those in this group with high-grade cytological findings. After incorporating detailed clinical guidelines recommendations, this strategy is predicted to reduce cervical cancer incidence and mortality by 31% and 36%, respectively, in unvaccinated cohorts, and by 24% and 29%, respectively, in cohorts offered vaccination. Furthermore, this strategy is predicted to reduce costs by up to 19% for unvaccinated cohorts and 26% for cohorts offered vaccination, compared with the current programme. INTERPRETATION: Primary HPV screening every 5 years with partial genotyping is predicted to be substantially more effective and potentially cost-saving compared with the current cytology-based screening programme undertaken every 2 years. These findings underpin the decision to transition to primary HPV screening with partial genotyping in the Australian National Cervical Screening Program, which will occur in May, 2017. FUNDING: Department of Health, Australia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61248-4 · Cited by 1,655
Dillner, J., Rebolj, M., Birembaut, P., Petry, K.-U., Szarewski, A., Munk, C., de Sanjose, S., Naucler, P., Lloveras, B., Kjaer, S., et al. (2008) · BMJ · doi:10.1136/bmj.a1754 · Cited by 629
Rijkaart, D., Berkhof, J. H., Rozendaal, L., van Kemenade, F. J., Bulkmans, N. W. J., Heideman, D. A. M., Kenter, G. G., Cuzick, J. M., Snijders, P. J. F., & Meijer, C. J. L. M. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70296-0 · Cited by 530
Tabrizi, S. N., Brotherton, J. M. L., Kaldor, J. M., Skinner, S. R., Liu, B., Bateson, D., McNamee, K., Garefalakis, M., Phillips, S., Cummins, E., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70841-2 · Cited by 301
Goldhaber‐Fiebert, J. D., Stout, N. K., Salomon, J. A., Kuntz, K. M., & Goldie, S. J. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn019 · Cited by 288
Kitchener, H. C., Gilham, C., Sargent, A., Bailey, A. C., Albrow, R., Roberts, C., Desai, M., Mather, J., Turner, A. J., Moss, S., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.008 · Cited by 175
Kitchener, H. C., Canfell, K., Gilham, C., Sargent, A., Roberts, C., Desai, M., & Peto, J. (2014) · Health Technology Assessment · doi:10.3310/hta18230 · Cited by 152
Self-citationElfstrom, K. M., Smelov, V., Johansson, A. L. V., Eklund, C., Naucler, P., Arnheim-Dahlstrom, L., & Dillner, J. (2014) · BMJ · doi:10.1136/bmj.g130 · Cited by 142
Brotherton, J. M. L., Murray, S. L., Hall, M., Andrewartha, L., Banks, C., Meijer, D., Pitcher, H. C., Scully, M., & Molchanoff, L. (2013) · The Medical Journal of Australia · doi:10.5694/mja13.10272 · Cited by 141
Self-citationCastle, P. E., Glass, A. G., Rush, B. B., Scott, D. R., Wentzensen, N., Gage, J. C., Buckland, J., Rydzak, G., Lorincz, A. T., & Wacholder, S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8389 · Cited by 113
Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus
Kim, J. J., Burger, E. A., Sy, S., & Campos, N. G. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw216 · Cited by 104
Human Papillomavirus (HPV) Vaccines: Limited Cross‐Protection against Additional HPV Types
Herrero, R. (2009) · The Journal of Infectious Diseases · doi:10.1086/597308 · Cited by 104
Smith, M. A., Liu, B. C., McIntyre, P. B., Menzies, R., Dey, A., & Canfell, K. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu370 · Cited by 83
Self-citationCost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway
Burger, E. A., Ortendahl, J. D., Sy, S., Kristiansen, I. S., & Kim, J. J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.94 · Cited by 80
Simms, K. T., Smith, M. A., Lew, J., Kitchener, H. C., Castle, P. E., & Canfell, K. (2016) · International Journal of Cancer · doi:10.1002/ijc.30392 · Cited by 77
Self-citationHPV vaccine impact in Australian women: ready for an HPV‐based screening program
Brotherton, J. M. L., Gertig, D. M., May, C. L., Chappell, G., & Saville, M. (2016) · The Medical Journal of Australia · doi:10.5694/mja15.01038 · Cited by 73
Self-citationBulkmans, N. W. J., Rozendaal, L., Voorhorst, F. J., Snijders, P. J. F., & Meijer, C. J. L. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602541 · Cited by 66
Brotherton, J. M. L., Liu, B. C., Donovan, B. J., Kaldor, J. M., & Saville, M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.11.075 · Cited by 63
Self-citationLew, J., Simms, K. T., Smith, M. A., Lewis, H., Neal, H., & Canfell, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151619 · Cited by 56
Self-citationSmith, M. A., Gertig, D. M., Hall, M. T., Simms, K. T., Lew, J., Malloy, M. J., Saville, M., & Canfell, K. (2016) · BMC Health Services Research · doi:10.1186/s12913-016-1375-9 · Cited by 49
Self-citationHow many cervical cancers are prevented by treatment of screen‐detected disease in young women?
Sasieni, P. D., Castañón, A., & Parkin, D. M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23922 · Cited by 40
Simms, K. T., Hall, M. T., Smith, M. A., Lew, J., Hughes, S., Yuill, S., Hammond, I. G., Saville, M., & Canfell, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0163509 · Cited by 37
Self-citationSimonella, L., & Canfell, K. (2013) · Cancer Causes & Control · doi:10.1007/s10552-013-0250-9 · Cited by 30
Self-citationExpenditure and resource utilisation for cervical screening in Australia
Lew, J., Howard, K., Gertig, D. M., Smith, M. A., Clements, M., Nickson, C., Shi, J., Dyer, S. M., Lord, S. J., Creighton, P., et al. (2012) · BMC Health Services Research · doi:10.1186/1472-6963-12-446 · Cited by 19
Self-citationAccetta, G., Biggeri, A., Carreras, G., Lippi, G., Carozzi, F., Confortini, M., Zappa, M., & Paci, E. (2010) · Journal of Medical Screening · doi:10.1258/jms.2010.010019 · Cited by 19
Cited by
Sorted by citations
Fontham, E. T. H., Wolf, A. M. D., Church, T. R., Etzioni, R., Flowers, C. R., Herzig, A., Guerra, C. E., Oeffinger, K. C., Shih, Y. T., Walter, L. C., et al. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21628 · Cited by 968
Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., Martin, D., Simms, K. T., Bénard, É., Boily, M.-C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30068-4 · Cited by 943
Self-citationCanfell, K., Kim, J. J., Brisson, M., Keane, A., Simms, K. T., Caruana, M., Burger, E. A., Martin, D., Nguyen, D. T. N., Bénard, É., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30157-4 · Cited by 650
Self-citationSimms, K. T., Steinberg, J., Caruana, M., Smith, M. A., Lew, J.-B., Soerjomataram, I., Castle, P. E., Bray, F., & Canfell, K. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30836-2 · Cited by 486
Self-citationThe projected timeframe until cervical cancer elimination in Australia: a modelling study
Hall, M. T., Simms, K. T., Lew, J., Smith, M. A., Brotherton, J. M. L., Saville, M., Frazer, I. H., & Canfell, K. (2018) · The Lancet Public Health · doi:10.1016/s2468-2667(18)30183-x · Cited by 448
Self-citation
Metadata
- Authors
- Lew, J.-B., Simms, K. T., Smith, M. A., Hall, M., Kang, Y.-J., Xu, X. M., Caruana, M., Velentzis, L. S., Bessell, T., Saville, M., Hammond, I., & Canfell, K.
- Affiliations
- Cancer Council NSW (AU)
- The University of Sydney (AU)
- Department of Health and Aged Care (AU)
- The University of Melbourne (AU)
- The University of Western Australia (AU)
- Corresponding author
- Canfell, Karen
- ORCID
- Venue
- The Lancet Public Health
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 2
- Issue
- 2
- Pages
- e96-e107
- ISSN
- 2468-2667 (ISSN-L)
- OpenAlex
- W2586260676
- Cited by
- 160
- References
- 26
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 11 · 2023: 13 · 2022: 17 · 2021: 19 · 2020: 32 · 2019: 25 · 2018: 19 · 2017: 6
- FWCI
- 17.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Lancet Public Health (publishedVersion, cc-by-nc-nd)
- UWA Profiles and Research Repository (UWA) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- The Sydney eScholarship Repository (The University of Sydney) (submittedVersion)
- Funders
- Multiple System Atrophy Coalition
- National Health and Medical Research Council (1082989, 440200, 1007518)
- Cancer Council NSW
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Keywords
- primary HPV testing, cervical cancer screening, HPV vaccination, HPV genotyping, HPV 16/18, colposcopy referral, cervical cancer incidence and mortality, cost-effectiveness, National Cervical Screening Program
- MeSH terms
- Adolescent, Adult, Aged, Australia, Uterine Cervical Neoplasms, Cost-Benefit Analysis, Cell Biology, Diagnostic Tests, Routine, Female, Humans, Middle Aged, Primary Prevention, Program Evaluation, Papillomavirus Infections, Papillomavirus Vaccines, Early Detection of Cancer, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
